Featured News
AIM Blog
Fifteen Years of Impact: A Movement Powered by Advocacy
This year marks a milestone in the fight against Alzheimer’s and other dementia: the fifteenth anniversary of the Alzheimer’s Impact Movement (AIM). Since its founding in 2010, I’ve seen AIM become a ...
All News
Press Release
Alzheimer's Association Welcomes U.S. FDA Traditional Approval of Leqembi
CHICAGO, July 6, 2023 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to grant traditional...
AIM Blog
Advocates in All 50 States Rally for Full Access to Alzheimer’s Treatments
During the past few weeks, the Alzheimer’s Association has been ramping up its efforts to make Food and Drug Administration...
AIM Blog
Recognizing AIM’s July Advocate of the Month: Matt Katawicz
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
AIM Blog
Taking Action During Alzheimer’s & Brain Awareness Month
More than 6 million Americans are living with Alzheimer’s. Throughout Alzheimer’s & Brain Awareness Month, federal and state policymakers and...
Press Release
Senate HELP Committee Advances Bipartisan Legislation to Renew Nation’s Commitment to Addressing the Alzheimer’s Crisis
NAPA Reauthorization Act and Alzheimer’s Accountability and Investment Act Washington, D.C., June 15, 2023 — Today the Senate Committee on...
Press Release
FDA Advisory Committee Unanimously Confirms Efficacy and Clinical Benefit of Leqembi for Early Alzheimer's Disease
CHICAGO, June 9, 2023 — Today, an Advisory Committee to the Food and Drug Administration (FDA) unanimously endorsed the efficacy...